AT179983T - Antiretroviral, enantiomeric nucleotide analogs - Google Patents

Antiretroviral, enantiomeric nucleotide analogs

Info

Publication number
AT179983T
AT179983T AT93918659T AT93918659T AT179983T AT 179983 T AT179983 T AT 179983T AT 93918659 T AT93918659 T AT 93918659T AT 93918659 T AT93918659 T AT 93918659T AT 179983 T AT179983 T AT 179983T
Authority
AT
Austria
Prior art keywords
antiretroviral
nucleotide analogs
enantiomeric nucleotide
enantiomeric
analogs
Prior art date
Application number
AT93918659T
Other languages
German (de)
Inventor
Antonin Holy
Hana Dvorakova
Erik Desire Alice Declercq
Jan Marie Rene Balzarini
Original Assignee
Acad Of Science Czech Republic
Rega Stichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US07/925,610 priority Critical patent/US6057305A/en
Application filed by Acad Of Science Czech Republic, Rega Stichting filed Critical Acad Of Science Czech Republic
Publication of AT179983T publication Critical patent/AT179983T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulfur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulfur or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6521Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
AT93918659T 1992-08-05 1993-08-04 Antiretroviral, enantiomeric nucleotide analogs AT179983T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/925,610 US6057305A (en) 1992-08-05 1992-08-05 Antiretroviral enantiomeric nucleotide analogs

Publications (1)

Publication Number Publication Date
AT179983T true AT179983T (en) 1999-05-15

Family

ID=25451994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918659T AT179983T (en) 1992-08-05 1993-08-04 Antiretroviral, enantiomeric nucleotide analogs

Country Status (13)

Country Link
US (3) US6057305A (en)
EP (2) EP0897917A1 (en)
JP (3) JP3561272B2 (en)
AT (1) AT179983T (en)
CA (2) CA2574904C (en)
CZ (2) CZ290797B6 (en)
DE (2) DE69324923D1 (en)
DK (1) DK0654037T3 (en)
ES (1) ES2131116T3 (en)
GR (1) GR3030754T3 (en)
HK (1) HK1011998A1 (en)
SG (1) SG47761A1 (en)
WO (1) WO1994003467A2 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995007919A1 (en) * 1993-09-17 1995-03-23 Gilead Sciences, Inc. Method for dosing therapeutic compounds
IT1270008B (en) * 1994-09-23 1997-04-16 Ist Superiore Sanita purine derivatives and 8-azapurinici acts for the therapeutic treatment of AIDS
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6197775B1 (en) * 1995-06-15 2001-03-06 Mitsubishi Chemical Corporation Phosphonate nucleotide derivatives
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CA2261619C (en) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
CN101239989B (en) * 1996-07-26 2012-12-12 吉联亚科学股份有限公司 Nucleotide analog
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
KR20000029952A (en) * 1996-08-13 2000-05-25 미우라 아끼라 Phosphonate nucleotide compounds
JP4173202B2 (en) * 1997-07-25 2008-10-29 ギリアード サイエンシーズ,インコーポレイテッド Nucleotide analog compositions and synthesis methods
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1243590B1 (en) * 1997-07-25 2005-02-09 Gilead Sciences Inc. Nucleotide analog composition and synthesis method
CN1307421C (en) 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 Method and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
BR9907736A (en) 1998-01-23 2000-10-17 Newbiotics Inc Enzyme-catalyzed therapeutic agents
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2001007088A2 (en) 1999-07-22 2001-02-01 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US20020103161A1 (en) * 1999-12-17 2002-08-01 Manfred Weigele Novel heterocycles
AU8294101A (en) 2000-07-21 2002-02-05 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
AU2002241911B9 (en) 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
CA2452036C (en) 2001-06-29 2009-09-29 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
WO2003028737A1 (en) * 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
JP2005519983A (en) * 2001-11-14 2005-07-07 バイオクリスト・ファマシューティカルズ インク. Nucleosides, their preparation, and their use as inhibitors of RNA viral polymerase
JP2006515624A (en) * 2003-01-14 2006-06-01 ギリアード サイエンシーズ, インコーポレイテッド Compositions and methods for combination antiviral therapy
US7115592B2 (en) 2003-06-16 2006-10-03 Institute Of Organic Chemistry Phosphonate substituted pyrimidine compounds and methods for therapy
JP2007517900A (en) * 2004-01-12 2007-07-05 ギリアード サイエンシーズ, インコーポレイテッド Pyrimidinephosphonate antiviral compounds and methods of use
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
UA93354C2 (en) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
JP2008520744A (en) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニアThe Regents of The University of California Anti-inflammatory pyrazolopyrimidine
ES2401285T3 (en) 2004-12-16 2013-04-18 The Regents Of The University Of California Drugs with lung as target
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
CA2606399A1 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic Use of compounds to enhance processivity of telomerase
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
WO2007068934A2 (en) * 2005-12-14 2007-06-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
KR20090017498A (en) * 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Pi3 kinase antagonists
JP5356228B2 (en) * 2006-07-07 2013-12-04 ギリアード サイエンシーズ, インコーポレイテッド Regulator of toll-like receptor 7
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20080318904A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched tenofovir
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX358640B (en) 2008-01-04 2018-08-29 Intellikine Llc Certain chemical entities, compositions and methods.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
ES2458358T3 (en) * 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
US20130216590A1 (en) 2010-06-11 2013-08-22 Quarraisha Abdool Karim Topical antiviral formulations for prevention of transmission of hsv-2
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
BR112013014485A2 (en) 2010-12-10 2016-09-20 Sigmapharm Lab Llc highly stable compositions of orally active nucleotide analogs or oredications of orally active nucleotide analogs
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
JP2014501790A (en) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ, インコーポレイテッド Process for the preparation of isoquinolinone and solid form of isoquinolinone
CN106619647A (en) 2011-02-23 2017-05-10 因特利凯有限责任公司 Combination of mtor inhibitors and pi3-kinase inhibitors and uses thereof
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9650346B2 (en) 2011-04-08 2017-05-16 Laurus Labs Private Ltd. Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
EP2707004A1 (en) 2011-05-10 2014-03-19 Okapi Sciences NV Compounds for use in the treatment of feline retroviral infections
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014000648A (en) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CN103917550B (en) 2011-11-16 2016-08-24 劳拉斯实验室私人有限公司 For the method preparing tenofovir
EP2794624B1 (en) * 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
KR20150061651A (en) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105246902B (en) 2013-03-15 2018-05-04 加利福尼亚大学董事会 Acyclic nucleoside phosphonate diester
CN104230934B (en) * 2013-06-08 2016-12-28 上海医药工业研究院 A kind of compound and its production and use
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2925944A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103641857B (en) * 2013-12-20 2016-08-24 石药集团中诺药业(石家庄)有限公司 A kind of Novel tenofovir crystal form and preparation method thereof
TWI660965B (en) 2014-01-15 2019-06-01 美商基利科學股份有限公司 Solid forms of tenofovir
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017005111A2 (en) 2014-09-15 2018-01-23 Univ California compounds, pharmaceutical composition, uses of a compound or a pharmaceutically acceptable salt thereof for the treatment of a host infected with a human papillomavirus, uses of a compound, method for the manufacture of a medicament for therapeutic use in the treatment of a papillomavirus infection
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB544419A (en) * 1940-01-08 1942-04-13 Union Special Machine Co Improvements in or relating to sewing machines
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4221910A (en) * 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
EP0274025A3 (en) * 1983-05-24 1990-08-29 Sri International Novel antiviral agents
PT78769A (en) * 1983-06-24 1984-07-01 Merck & Co Inc Process for preparing (s)-9-(2,3-dihydroxy-1-propoxymethyl)guanine and derivatives thereof useful as antiviral agents
US4556727A (en) * 1984-07-18 1985-12-03 University Patents, Inc. Ferroelectric smectic liquid crystals
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US4851387A (en) * 1986-10-14 1989-07-25 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use
IL84477A (en) * 1986-11-18 1995-12-08 Squibb Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions containing them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
DE3883070T2 (en) * 1987-05-18 1994-01-27 Canon Kk Polymer liquid crystal composition and liquid crystal device.
JP2580205B2 (en) * 1987-10-21 1997-02-12 チッソ株式会社 Optically active-2-biphenylylpyridines
NO172846C (en) * 1987-12-25 1993-09-15 Daiichi Seiyaku Co A process for the preparation of 7,8-dihalo-3-methyl-2,3-dihydro-2M-benzoxazine and propoksybenzenderivater for utoevelse Procedure.
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
AU4376589A (en) * 1988-11-07 1990-05-10 Gist-Brocades N.V. Optically active benzoxazines and benzothiazines
DE3906357A1 (en) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh New acyclic nucleoside analogues, methods for their manufacture and use of these compounds as antiviral drug
AT124050T (en) * 1990-04-20 1995-07-15 Acad Of Science Czech Republic Chirale 2- (phosphonomethoxy) propyl guanine as antiviral agents.
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
SK280313B6 (en) * 1990-04-24 1999-11-08 Ústav organické chemie a biochemie AV ČR N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, process for their preparation and their use
CS387190A3 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
WO1992002511A1 (en) * 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
DE69129650T2 (en) * 1990-09-14 1999-03-25 Acad Of Science Czech Republic Precursor of phosphonates
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EP0763048A1 (en) * 1994-05-31 1997-03-19 Medivir Aktiebolag Post exposure prevention of hiv

Also Published As

Publication number Publication date
US6057305A (en) 2000-05-02
JP4083691B2 (en) 2008-04-30
JP2004189750A (en) 2004-07-08
GR3030754T3 (en) 1999-11-30
DE69324923D1 (en) 1999-06-17
CA2574904C (en) 2009-06-16
CZ290797B6 (en) 2002-10-16
EP0654037B1 (en) 1999-05-12
WO1994003467A3 (en) 1994-06-23
CA2141589A1 (en) 1994-02-17
WO1994003467A2 (en) 1994-02-17
JP2008120820A (en) 2008-05-29
ES2131116T3 (en) 1999-07-16
CA2574904A1 (en) 1994-02-17
HK1011998A1 (en) 2000-10-05
EP0654037A1 (en) 1995-05-24
SG47761A1 (en) 1998-04-17
CA2141589C (en) 2007-04-17
DK0654037T3 (en) 1999-11-01
JPH08503927A (en) 1996-04-30
DE69324923T2 (en) 1999-11-25
JP3561272B2 (en) 2004-09-02
US6653296B1 (en) 2003-11-25
DK654037T3 (en)
US6479673B1 (en) 2002-11-12
CZ293533B6 (en) 2004-05-12
EP0897917A1 (en) 1999-02-24
CZ27295A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
DE3789873D1 (en) Immunaffinity cleaning system.
DE3650042D1 (en) Pesticidal process using N-phenylpyrazoles.
DE3781739T2 (en) Fastening arrangement.
DE69330004T2 (en) Virtual printer
DE3875631T2 (en) Working environment system.
DE3775972D1 (en) Eliminating sulfur compounds.
DE3768976D1 (en) Mediation system.
DE3650046T2 (en) Sprayer.
DE69801802D1 (en) Substituted propargylethoxyamido nucleosides
DE69703298D1 (en) Propargylethoxyamino nucleotide
DE3770705D1 (en) Scratch-resistant plasma coating.
DE69010633D1 (en) Perfluorovinyl compounds.
DK0526253T3 (en) 1,3-oxathiolane nucleoside analogues
DE69231441T2 (en) Main chain modified oligonucleotide analogs
DE69003767T2 (en) Overhead console.
DE69427207T2 (en) Routing to intelligence
DE3680060D1 (en) Multiplex structure.
DE3788605T2 (en) Packet switching.
DE69321962T2 (en) Transportpolypeptides derived from act
DE69330608D1 (en) Positional sequencing through hybridization
DK1137666T5 (en) GLP-1 analogs
FR2651625B1 (en) Packet telecommunications system.
DE3785131T2 (en) Suit.
DE69424861D1 (en) Geminivirus-based gene expression system
DE3851187D1 (en) 3'-azido-2 ', 3'-dideoxyuridine anti-retroviral composition.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification